Torrent Pharmaceuticals Ltd Enters into Co-Marketing Partnership with Boehringer Ingelheim India Private Limited to Co-Market Its Anti-Diabetic Drug and Its Fixed Dose Combinations in India
December 14, 2022 at 05:06 am EST
Share
Torrent Pharmaceuticals Ltd. has entered into a strategic alliance with Boehringer Ingelheim India Private Limited ("BI India") to co-market Cospiaq® (Empagliflozin), Cospiaq MetTM (Empagliflozin+ Metformin) and Xilingio ® (Empagliflozin+ Linagliptin) in India. Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus. Empagliflozin is also indicated to reduce the risk of cardiovascular death, in adults with type 2 diabetes mellitus and established cardiovascular disease.
Further, empagliflozin is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure, in adults with heart failure.
Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain, gynecology, and dermatology. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its acne/facecare products brands include Clinmiskin, ACNEMOIST, TRACNILO and fash. The Company's hair/scalp care products brands include Proanagen, Perlice, Permite and NOSKURF. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim. The Company's primary channel of distribution is through the wholesale drug distributors, stockiest and retail pharmacies.
Torrent Pharmaceuticals Ltd Enters into Co-Marketing Partnership with Boehringer Ingelheim India Private Limited to Co-Market Its Anti-Diabetic Drug and Its Fixed Dose Combinations in India
TORRENT PHARMACEUTICALS LIMITED 
